MX2023009610A - Esteroides neuroactivos, y su metodo de uso. - Google Patents

Esteroides neuroactivos, y su metodo de uso.

Info

Publication number
MX2023009610A
MX2023009610A MX2023009610A MX2023009610A MX2023009610A MX 2023009610 A MX2023009610 A MX 2023009610A MX 2023009610 A MX2023009610 A MX 2023009610A MX 2023009610 A MX2023009610 A MX 2023009610A MX 2023009610 A MX2023009610 A MX 2023009610A
Authority
MX
Mexico
Prior art keywords
methods
pharmaceutically acceptable
compound
neuroactive steroids
related disorders
Prior art date
Application number
MX2023009610A
Other languages
English (en)
Inventor
Stephen Jay Kanes
Ethan Hoffmann
George Nomikos
Handan Gunduz-Bruce
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2023009610A publication Critical patent/MX2023009610A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se refiere al Compuesto 1: (ver Fórmula) (Compuesto 1) sales farmacéuticamente aceptables, o composiciones farmacéuticamente aceptables del mismo, para el tratamiento de trastornos relacionados con el SNC, por ej. temblor, por ej. temblor esencial; depresión; y trastorno de la ansiedad, y métodos para mejorar la efectividad de la administración del Compuesto 1 para tratar dichos trastornos relacionados con el SNC. La invención también se refiere a métodos para incrementar la biodisponibilidad de un Compuesto 1 o sales farmacéuticamente aceptables, o composiciones farmacéuticamente aceptables del mismo.
MX2023009610A 2017-09-07 2020-03-06 Esteroides neuroactivos, y su metodo de uso. MX2023009610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555404P 2017-09-07 2017-09-07
US201762595998P 2017-12-07 2017-12-07

Publications (1)

Publication Number Publication Date
MX2023009610A true MX2023009610A (es) 2023-08-24

Family

ID=63794613

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020002652A MX2020002652A (es) 2017-09-07 2018-09-07 Esteroides neuroactivos y su método de uso.
MX2023009611A MX2023009611A (es) 2017-09-07 2020-03-06 Esteroides neuroactivos, y su metodo de uso.
MX2023009610A MX2023009610A (es) 2017-09-07 2020-03-06 Esteroides neuroactivos, y su metodo de uso.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2020002652A MX2020002652A (es) 2017-09-07 2018-09-07 Esteroides neuroactivos y su método de uso.
MX2023009611A MX2023009611A (es) 2017-09-07 2020-03-06 Esteroides neuroactivos, y su metodo de uso.

Country Status (11)

Country Link
US (2) US20200281943A1 (es)
EP (1) EP3678670A1 (es)
JP (3) JP2020533310A (es)
CN (2) CN117771252A (es)
AU (2) AU2018327357B2 (es)
CA (1) CA3075038A1 (es)
IL (2) IL303250A (es)
MX (3) MX2020002652A (es)
SG (1) SG11202002085YA (es)
TW (2) TW201919641A (es)
WO (1) WO2019051264A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
HUE041369T2 (hu) 2013-04-17 2019-05-28 Sage Therapeutics Inc 19-nor C3,3-diszubsztituált C21-N-pirazolil-szteroidok és eljárás ezek alkalmazására
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
CA3199003A1 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA3235088A1 (en) 2013-08-23 2015-02-26 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MX2017005002A (es) 2014-10-16 2018-01-23 Sage Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos del snc.
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
RS61530B1 (sr) 2015-01-26 2021-04-29 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
IL309259A (en) 2016-07-11 2024-02-01 Sage Therapeutics Inc C17, C20 and C21 converted neuroactive steroids and methods of using them
JP7065825B2 (ja) 2016-07-11 2022-05-12 セージ セラピューティクス， インコーポレイテッド Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法
AR109393A1 (es) 2016-08-23 2018-11-28 Sage Therapeutics Inc Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino
JP2021505608A (ja) 2017-12-08 2021-02-18 セージ セラピューティクス， インコーポレイテッド ＣＮＳ障害を処置するためのジュウテリウム化された２１−［４−シアノ−ピラゾール−１−イル］−１９−ノル−プレガン−３．α−オール−２０−オン誘導体
KR20210021005A (ko) * 2018-06-12 2021-02-24 세이지 테라퓨틱스, 인크. 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
MA56046A (fr) 2019-05-31 2022-04-06 Sage Therapeutics Inc Stéroïdes neuroactifs et compositions associées
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
EP4069250A1 (en) * 2019-12-05 2022-10-12 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
WO2021195297A1 (en) 2020-03-25 2021-09-30 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
AU2021312240A1 (en) * 2020-07-20 2023-02-02 Sage Therapeutics, Inc. Formulations of 19-nor C3,3- disubstituted C21-n-pyrazolyl steroid and methods of use thereof
EP4199724A4 (en) * 2020-10-01 2024-09-25 Eliem Therapeutics Uk Ltd METHODS FOR TREATING GABA-MEDIATED DISEASES
EP4199723A4 (en) * 2020-10-01 2024-09-04 Eliem Therapeutics Uk Ltd METHODS FOR TREATING FIBROMYALGIA WITH NEUROACTIVE STEROIDS
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1888080E (pt) * 2005-06-09 2010-07-06 Euro Celtique Sa ComposiãŽes farmac—uticas de um esterëide neuroactivo e as suas utilizaãŽes
EP2155204B1 (en) * 2007-06-15 2016-08-17 Research Triangle Institute Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
HUE041369T2 (hu) * 2013-04-17 2019-05-28 Sage Therapeutics Inc 19-nor C3,3-diszubsztituált C21-N-pirazolil-szteroidok és eljárás ezek alkalmazására
KR102408399B1 (ko) * 2016-03-08 2022-06-13 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
AR109393A1 (es) * 2016-08-23 2018-11-28 Sage Therapeutics Inc Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino

Also Published As

Publication number Publication date
WO2019051264A1 (en) 2019-03-14
JP2020533310A (ja) 2020-11-19
IL303250A (en) 2023-07-01
TW202342058A (zh) 2023-11-01
AU2018327357A1 (en) 2020-03-26
SG11202002085YA (en) 2020-04-29
IL273099A (en) 2020-04-30
JP2023033543A (ja) 2023-03-10
JP2024133114A (ja) 2024-10-01
AU2024205519A1 (en) 2024-08-22
MX2023009611A (es) 2023-08-24
EP3678670A1 (en) 2020-07-15
US20230310459A1 (en) 2023-10-05
TW201919641A (zh) 2019-06-01
CN117771252A (zh) 2024-03-29
CA3075038A1 (en) 2019-03-14
MX2020002652A (es) 2020-09-25
US20200281943A1 (en) 2020-09-10
AU2018327357B2 (en) 2024-08-22
CN111491637A (zh) 2020-08-04

Similar Documents

Publication Publication Date Title
MX2023009611A (es) Esteroides neuroactivos, y su metodo de uso.
MX2021004492A (es) Composiciones para el tratamiento de trastornos del snc.
MX2023002004A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2022016276A (es) Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
MX2017011951A (es) Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.
MX2019008626A (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
PH12019500196A1 (en) Compounds and compositions and uses thereof
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
SG10201907289VA (en) Monomethylfumarate prodrug compositions
PH12021550671A1 (en) Prodrugs of cgrp antagonists
NZ736551A (en) Indole derivatives
JOP20180057A1 (ar) مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6